M. Aizawa

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

M. Kudo, J. Furuse, M. Kurosaki, 2021, Liver Cancer.

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.

R. Motzer, H. Miyake, Y. Umeyama, 2023, ESMO open.

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study

M. Hino, K. Ishizawa, I. Matsumura, 2022, International Journal of Hematology.

Real‐world outcomes of avelumab plus axitinib as first‐line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J‐DART)

T. Miyagawa, N. Hinata, M. Nozawa, 2023, International journal of urology : official journal of the Japanese Urological Association.

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).

M. Kudo, J. Furuse, M. Kurosaki, 2019, Journal of Clinical Oncology.